Randal Scott Sells 10,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Randal Scott sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $75.46, for a total transaction of $754,600.00. Following the sale, the director owned 11,589 shares in the company, valued at $874,505.94. The trade was a 46.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

BridgeBio Pharma Trading Down 4.3%

BridgeBio Pharma stock opened at $70.72 on Friday. The firm has a 50 day simple moving average of $75.66 and a 200 day simple moving average of $63.84. BridgeBio Pharma, Inc. has a 1-year low of $28.33 and a 1-year high of $84.94. The firm has a market capitalization of $13.63 billion, a price-to-earnings ratio of -16.92 and a beta of 1.13.

Analyst Upgrades and Downgrades

Several brokerages have commented on BBIO. Raymond James Financial set a $89.00 target price on BridgeBio Pharma and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Barclays started coverage on shares of BridgeBio Pharma in a research report on Wednesday, January 28th. They issued an “overweight” rating for the company. Evercore reaffirmed an “outperform” rating on shares of BridgeBio Pharma in a research note on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Pharma in a research note on Wednesday, January 21st. Finally, Truist Financial boosted their price target on shares of BridgeBio Pharma from $80.00 to $86.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $82.05.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL‑3 achondroplasia results improve the program’s regulatory and commercial outlook — a clear fundamental catalyst supporting upside for BBIO. Read More.
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates and bumped its price target to $100 while keeping a Buy rating — analyst upgrades can lift sentiment and buying interest. Read More.
• Neutral Sentiment: Upcoming Q4/2025 earnings and Feb. 24 conference call create a scheduled event risk: results and program/cash‑burn details could drive short‑term volatility either way. Read More.
• Neutral Sentiment: Company granted inducement RSUs to new hires (76,701 shares) — modest ongoing dilution to monitor but not a large immediate overhang. Read More.
• Neutral Sentiment: Small institutional buying: Oppenheimer reported a new 7,845‑share stake per 13F filing — signals some investor interest but immaterial scale. Read More.
• Negative Sentiment: Clustered insider selling on Feb. 17: Director Randal Scott sold 10,000 shares (~$754k) and the CFO sold 13,600 shares (~$1.02M), alongside other officer sales — concentrated disposals are pressuring near‑term sentiment. Read More.
• Negative Sentiment: Smaller CAO sale (510 shares) and a pattern of executive liquidity events — repeated sales by insiders can keep downward pressure until management rebuilds conviction via buying or other signals. Read More.
• Neutral Sentiment: Reported short‑interest data is inconsistent (entries show zero shares / NaN) and does not currently indicate a material short‑squeeze dynamic — treat the short‑interest note as noise until clearer reporting emerges.

Hedge Funds Weigh In On BridgeBio Pharma

A number of institutional investors have recently made changes to their positions in BBIO. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of BridgeBio Pharma during the 2nd quarter worth $25,000. Aster Capital Management DIFC Ltd purchased a new stake in BridgeBio Pharma during the third quarter valued at about $31,000. Harvest Fund Management Co. Ltd bought a new stake in BridgeBio Pharma during the third quarter worth about $34,000. Jones Financial Companies Lllp purchased a new position in shares of BridgeBio Pharma in the 1st quarter worth about $35,000. Finally, First Horizon Corp bought a new position in shares of BridgeBio Pharma during the 3rd quarter valued at about $36,000. Institutional investors own 99.85% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.